Ratings by Guggenheim (Debjit Chattopadhyay)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/23/2026 | Editas Medicine | EDIT | Upgrade | Buy (Neutral) |
2.93 (2.49) |
-15.02% | Details | |
| 9/15/2026 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2026 | Pharvaris B.V. | PHVS | Maintain | Buy (N/A) |
|
Details | ||
| 8/18/2026 | Scribe Therapeutics Inc | SCTX | New Coverage | Buy (N/A) |
20.73 (17.96) |
-13.36% | Details | |
| 8/17/2026 | Spruce Biosciences, Inc. | SPRB | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2026 | Pharvaris B.V. | PHVS | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2026 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 7/21/2026 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 7/6/2026 | Edgewise Therapeutics | EWTX | Maintain | Buy (N/A) |
|
Details | ||
| 7/2/2026 | Edgewise Therapeutics | EWTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2026 | Spruce Biosciences, Inc. | SPRB | New Coverage | Buy (N/A) |
49.91 (46.00) |
-7.83% | Details | |
| 6/15/2026 | Rezolute | RZLT | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2026 | Benitec BioPharma | BNTC | Downgrade | Neutral (Buy) |
10.81 (8.82) |
-18.41% | Details | |
| 6/8/2026 | Entrada Therapeutics | TRDA | Maintain | Buy (N/A) |
|
Details | ||
| 6/5/2026 | Entrada Therapeutics | TRDA | Maintain | Buy (N/A) |
|
Details | ||
| 6/4/2026 | Opus Genetics | IRD | New Coverage | Buy (N/A) |
4.20 (3.82) |
-9.05% | Details | |
| 5/8/2026 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2026 | Neurogene | NGNE | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2026 | Satellos Bioscience Inc. | MSLE | New Coverage | Buy (N/A) |
7.16 (6.63) |
-7.4% | Details | |
| 4/1/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Neutral (Buy) |
39.72 (40.50) |
1.96% | Details | |
| 3/20/2026 | Solid Biosciences | SLDB | New Coverage | Buy (N/A) |
7.12 (6.19) |
-13.06% | Details | |
| 2/19/2026 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2026 | PepGen Inc. | PEPG | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2026 | Entrada Therapeutics | TRDA | New Coverage | Buy (N/A) |
10.55 (4.73) |
-55.17% | Details | |
| 1/5/2026 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2025 | Maze Therapeutics | MAZE | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2025 | Rezolute | RZLT | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2025 | Pharvaris B.V. | PHVS | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2025 | Centessa Pharmaceuticals | CNTA | Maintain | Buy (N/A) |
|
Details | ||
| 10/27/2025 | Intellia Therapeutics | NTLA | Downgrade | Neutral (Buy) |
25.60 (11.16) |
-56.41% | Details | |
| 9/25/2025 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2025 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2025 | Maze Therapeutics | MAZE | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2025 | PepGen Inc. | PEPG | New Coverage | Buy (N/A) |
1.49 (2.70) |
81.21% | Details | |
| 8/13/2025 | Prime Medicine | PRME | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2025 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2025 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/11/2025 | Pharvaris B.V. | PHVS | New Coverage | Buy (N/A) |
18.12 (30.68) |
69.32% | Details | |
| 5/12/2025 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2025 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2025 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 4/30/2025 | Edgewise Therapeutics | EWTX | New Coverage | Buy (N/A) |
15.46 (39.99) |
158.67% | Details | |
| 3/28/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2025 | Maze Therapeutics | MAZE | New Coverage | Buy (N/A) |
12.09 (31.95) |
164.27% | Details | |
| 11/15/2024 | Centessa Pharmaceuticals | CNTA | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2024 | Benitec BioPharma | BNTC | New Coverage | Buy (N/A) |
8.44 (8.82) |
4.5% | Details | |
| 8/27/2024 | Rezolute | RZLT | New Coverage | Buy (N/A) |
4.70 (3.86) |
-17.87% | Details | |
| 8/14/2024 | Dyne Therapeutics | DYN | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2024 | CRISPR Therapeutics | CRSP | New Coverage | Neutral (N/A) |
55.38 (49.99) |
-9.73% | Details | |
| 4/30/2024 | Precision BioSciences Inc. | DTIL | New Coverage | Buy (N/A) |
9.84 (6.78) |
-31.1% | Details | |
| 4/16/2024 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/18/2024 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Buy (N/A) |
16.75 (21.58) |
28.84% | Details | |
| 12/21/2023 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2023 | Soleno Therapeutics Inc. | SLNO | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2023 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 11/21/2023 | Soleno Therapeutics Inc. | SLNO | New Coverage | Buy (N/A) |
27.96 (53.01) |
89.59% | Details | |
| 8/14/2023 | Centessa Pharmaceuticals | CNTA | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2023 | Prime Medicine | PRME | New Coverage | Buy (N/A) |
14.84 (3.73) |
-74.87% | Details | |
| 6/12/2023 | Centessa Pharmaceuticals | CNTA | New Coverage | Buy (N/A) |
4.61 (39.72) |
761.61% | Details | |
| 1/26/2023 | Dyne Therapeutics | DYN | New Coverage | Buy (N/A) |
13.51 (15.77) |
16.73% | Details | |
| 10/13/2022 | Ultragenyx Pharma | RARE | Upgrade | Buy (Neutral) |
38.47 (15.95) |
-58.54% | Details | |
| 6/27/2022 | Alnylam Pharmaceuticals | ALNY | Downgrade | Neutral (Buy) |
147.50 (227.28) |
54.09% | Details | |
| 5/2/2022 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 4/5/2022 | Taysha Gene Therapies | TSHA | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2022 | Ionis Pharmaceuticals | IONS | New Coverage | Buy (N/A) |
33.38 (43.91) |
31.55% | Details | |
| 3/1/2022 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2022 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2022 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2022 | Alnylam Pharmaceuticals | ALNY | Upgrade | Buy (Neutral) |
145.26 (227.28) |
56.46% | Details | |
| 1/5/2022 | Beam Therapeutics Inc | BEAM | New Coverage | Buy (N/A) |
78.31 (24.56) |
-68.64% | Details | |
| 12/16/2021 | Taysha Gene Therapies | TSHA | New Coverage | Buy (N/A) |
14.24 (4.01) |
-71.84% | Details | |
| 12/1/2021 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/5/2021 | Intellia Therapeutics | NTLA | New Coverage | (N/A) |
126.78 (11.16) |
-91.2% | Details | |
| 7/15/2021 | Ultragenyx Pharma | RARE | New Coverage | Neutral (N/A) |
84.74 (38.47) |
-54.6% | Details | |
| 5/6/2021 | Freeline | FRLN | New Coverage | Buy (N/A) |
11.25 (6.48) |
-42.4% | Details | |
| 1/7/2021 | Sangamo BioSciences | SGMO | New Coverage | Neutral (N/A) |
16.01 (0.18) |
-98.88% | Details | |
| 1/6/2021 | uniQure BV | QURE | Upgrade | Buy (Neutral) |
37.77 (23.11) |
-38.81% | Details |
